CPhA Sponsored Bills
- AB 299 (Holden): Patient Choice in Mail Order Pharmacy
Prohibits a nonresident or in-state pharmacy that delivers prescription drugs by mail from entering into an agreement with a health plan or insurer that requires patients to “opt out” of mail order programs.
- SB 493 (Hernandez): Provider Status
Declares pharmacists as providers; modifies pharmacist scope of practice in such a way that better enables pharmacists to participate in medical homes; establishes Advanced Practice Pharmacist category that gives pharmacists who meet specified requirements authorities that are currently limited to practicing in a hospital or health system.
- AB 804 (Lowenthal): AAC Cleanup
CPhA is working with the California Retailers Association to clarify to existing law regarding calculation of Average Acquisition Cost (AAC) and professional dispensing fees in the Medi-Cal program.
Other Pharmacy-Related Bills
- AB 219 (Perea): Outpatient Antineoplastic Cost Sharing Maximum
Prohibits a health plan or insurer that covers outpatient prescription drugs from requiring a beneficiary to pay more than $100 in copayment or coinsurance per fill of an anticancer medication.
- AB 403 (Stone): Sharps Takeback Program
Requires sharps manufacturers to develop and implement a product stewardship plan for sharps waste. Would not require pharmacies to participate, but pharmacies may be able to participate at their option.
- AB 635 (Ammiano): Opiate Antagonists
Authorizes a prescriber to prescribe and dispense an opiate antagonist to a patient at risk of an opiate overdose or a family member, friend, or other person in a position to assist a person at risk of an overdose.
- AB 670 (Atkins): Therapeutic Substitution
Prohibits a pharmacist or pharmacist employer from receiving any form of compensation as an inducement to recommend or replace an originally prescribed drug with another product that does not have the same active chemical ingredients.
- AB 1136 (Levine): Label Requirements
Requires a pharmacist to include a notice on a prescription drug bottle for prescription drugs that pose a risk when taken with alcohol or when taken alone, noting that the drug may impair a person’s ability to drive a vehicle or vessel.
- AB 1139 (Lowenthal): PBM/GPhA-Sponsored Biosimilar Substitution
Authorizes a pharmacist to substitute a biosimilar product approved by the FDA as interchangeable with a biologic product, in the same way that generic drugs can be substituted.
- AB 1202 (Skinner): Health Facility Antineoplastic Safety Requirements
Requires Cal-OSHA to adopt a standard, consistent with federal NIOSH recommendations, for the handling of antineoplastic and other hazardous drugs in health care facilities regardless of the setting.
- AB 1208 (Pan): Medical Homes
Defines a patient centered medical home as a health care delivery model.
- AB 1340 (Achadjian): State Hospital Employee Safety
Requires each state hospital to establish and maintain “enhanced treatment units” for the care of patients who have assaulted hospital employees or other patients.
- SB 62 (Price): Coroner Reporting of Prescription Drug Deaths
Requires county coroners to report deaths that may be the result of prescription drug use to the Board of Pharmacy and Medical Board.
- SB 146 (Lara): Workers Compensation Pharmacy Cleanup
Fixes an oversight that requires a copy of a prescription to be attached to workers compensation pharmacy reimbursement claims, and allows pharmacies to resubmit claims that have been denied for lack of the prescription attachment.
- SB 204 (Corbett): Prescription Drug Labels Translations
Requires a pharmacist to use translations of standardized directions published on the Board of Pharmacy’s website when labeling a prescription container and authorizes a pharmacist to translate the directions into additional languages.
- SB 205 (Corbett): Prescription Drug Labels Font Size
Requires the information on a prescription drug label to be in at least 12-point font.
- SB 294 (Emmerson): Nonresident Sterile Compounding
Prohibits an in-state or nonresident pharmacy from compounding sterile drug products unless the pharmacy has obtained a sterile compounding pharmacy license from the Board of Pharmacy, and establishes licensing requirements.
- SB 445 (Price): Advertisements for Controlled Substances
Prohibits pharmacy advertisements from specifically promoting the sale or dispensing of controlled substances.
- SB 506 (Hill): Pseudoephedrine (PSE)
Revises limits on the nonprescription sale of PSE products from 3 packages or 9 grams per transaction to 9 grams in 30 days or 3.6 grams in a single day. Requires retailers to transmit sales of PSE products to the National Precursor Log Exchange (NPLEx).
- SB 598 (Hill): Genentech/Amgen Biosimilar Substitutions
Authorize a pharmacist to substitute a biosimilar product approved by the FDA as interchangeable with a biologic product, and requires the pharmacist to notify the prescriber within five business days.
- SB 669 (Huff): Epinephrine Autoinjectors
Authorizes certain first responders to use an epi-pen in rendering emergency care, pursuant to training requirements and operational standards and provides immunity from civil liability. Authorizes pharmacies to dispense these epi-pens.
- SB 727 (Jackson): Prescription Drug Takeback Program
Requires prescription drug manufacturers to develop and implement a product stewardship plan for pharmaceutical waste. Would not require pharmacies to participate, but pharmacies may be able to participate at their option.
- SB 809 (DeSaulnier): Controlled Substance Utilization Review and Evaluation System (CURES)
Requires all prescribers and dispensers of controlled substances to register for access to the CURES program. Requires prescribers and dispensers to access and consult CURES information prior to prescribing or dispensing a Schedule II, III, or IV controlled substance. Establishes a fee on prescribers and dispensers of controlled substances, and wholesalers and veterinary food-animal drug retailers, in an amount of up to 1.16% of licensing fees, and a tax on drug manufacturers and health insurers, to fund the CURES program.